Finepoint Capital LP Ascendis Pharma A/S Transaction History
Finepoint Capital LP
- $963 Million
- Q3 2024
A detailed history of Finepoint Capital LP transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Finepoint Capital LP holds 190,072 shares of ASND stock, worth $24.4 Million. This represents 2.95% of its overall portfolio holdings.
Number of Shares
190,072
Previous 189,272
0.42%
Holding current value
$24.4 Million
Previous $25.8 Million
9.97%
% of portfolio
2.95%
Previous 7.43%
Shares
9 transactions
Others Institutions Holding ASND
# of Institutions
241Shares Held
58.8MCall Options Held
250KPut Options Held
377K-
Ra Capital Management, L.P. Boston, MA9.71MShares$1.24 Billion20.22% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.13MShares$658 Million3.62% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.99MShares$640 Million11.21% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.41MShares$566 Million1.03% of portfolio
-
Janus Henderson Group PLC London, X04.19MShares$537 Million0.33% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $7.15B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...